Regeneron Pharmaceuticals, INC 8-K filings

Regeneron Pharmaceuticals announced a 17% revenue increase to $4.3 billion in Q2 2026, driven by significant growth in key products like Dupixent, EYLEA HD, and Libtayo.

Regeneron Pharmaceuticals anticipates a pre-tax acquired in-process research and development charge of approximately $127 million for the second quarter of 2026, impacting net income per diluted share by an estimated $1.00.

Regeneron Pharmaceuticals announced a 19% revenue increase to $3.6 billion for Q1 2026, driven by strong Dupixent and EYLEA HD sales, alongside significant pipeline advancements and a new $3 billion share repurchase program.

Regeneron Pharmaceuticals anticipates a significant acquired in-process R&D charge impacting its first quarter 2026 earnings.

Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, highlighting significant growth in Dupixent and EYLEA HD sales alongside pipeline advancements.

Regeneron Pharmaceuticals provided a corporate update at the J.P. Morgan Healthcare Conference, detailing preliminary Q4 2025 financial impacts and a robust pipeline targeting significant market opportunities.

Regeneron Pharmaceuticals reported a 1% revenue increase to $3.75 billion in Q3 2025, driven by strong Dupixent sales, while EYLEA U.S. sales significantly decreased and EYLEA HD faced a manufacturing-related regulatory setback.

Regeneron Pharmaceuticals expects an approximate $83 million pre-tax acquired in-process research and development charge for the third quarter of 2025, impacting diluted EPS by $0.68.

Regeneron Pharmaceuticals announced a 4% increase in total revenues and a 12% rise in non-GAAP EPS for Q2 2025, driven by Dupixent and EYLEA HD sales, alongside multiple FDA approvals and strategic pipeline expansion despite EYLEA sales decline and regulatory delays.

Regeneron Pharmaceuticals, Inc. announced the results of its 2025 Annual Meeting of Shareholders, where key proposals including director elections and board declassification were approved, while amendments to eliminate supermajority voting requirements failed.

Regeneron announces its Q1 2025 financial results, highlighting growth in Dupixent and EYLEA HD sales but facing headwinds with overall EYLEA sales and providing updates on its extensive pipeline.

Regeneron announces a 10% increase in Q4 revenues and the initiation of a quarterly dividend program alongside an expanded share repurchase authorization.

Regeneron shares corporate progress and highlights from its broad and diverse investigational pipeline at the annual J.P. Morgan Healthcare Conference.

Regeneron's third quarter 2024 financial results show an 11% increase in revenue, driven by strong sales of Dupixent and EYLEA, and significant pipeline advancements.

Regeneron Pharmaceuticals anticipates a $56 million pre-tax charge related to acquired in-process research and development (IPR&D) that will negatively impact its third-quarter 2024 earnings per share by approximately $0.43.

Regeneron's second quarter 2024 results show a 12% increase in revenue, driven by strong sales of EYLEA HD, Dupixent, and Libtayo, and the European Commission approved Dupixent for COPD.

Regeneron Pharmaceuticals expects a $24 million pre-tax charge related to acquired in-process research and development to negatively impact its second quarter 2024 earnings by approximately $0.18 per diluted share.

Regeneron Pharmaceuticals held its 2024 Annual Meeting of Shareholders on June 14, 2024, where shareholders voted on the election of directors, ratification of the accounting firm, executive compensation, and a shareholder proposal.

Regeneron's first quarter 2024 revenues saw a slight decrease of 1% year-over-year, though excluding Ronapreve, revenues increased by 7%, with notable growth in Dupixent and Libtayo sales.

Regeneron's fourth-quarter revenue saw a modest 1% increase, but excluding Ronapreve, revenue grew by 14%, with significant advancements in their pipeline and strategic acquisitions.

Regeneron Pharmaceuticals has appointed Christopher Fenimore as its new Chief Financial Officer and Jason Pitofsky as Controller, effective after the filing of the 2023 annual report.